CRISPR Therapeutics (CRSP) Stock Forecast & Price Target

Crispr Therapeutics is poised for significant growth, particularly in 2026, as the company plans to expand its investment into additional indications, anticipating a notable acceleration in sales driven by increased patient starts and a sizable patient funnel. With the first approved drug, Casgevy, demonstrating strong potential for exceeding sales expectations due to heightened demand and favorable reimbursement conditions, the company expects to reach approximately $270 million in sales by 2026. Furthermore, advancements in gene editing programs, such as CTX320 and CTX321, which show promising editing efficiencies, coupled with strategic initiatives in various therapeutic areas, underscore a robust outlook for the company’s financial performance.

CRISPR Therapeutics faces a significant negative outlook primarily due to the inherent risks associated with drug development and potential regulatory hurdles that could impede product approval, resulting in downward revisions of financial projections and price targets. Additionally, if sales of its approved drug, Casgevy, do not accelerate or if early-stage programs are discontinued, the company's stock could experience a further decline, with a bear case scenario suggesting a 30% downside from base case estimates. Furthermore, any changes to partnership agreements, such as the recent licensing arrangement between Vertex and Editas, could lead to increased expenditures and negatively impact the company's share price.